CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc., a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. In addition, Voyager Therapeutics granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price to cover overallotments, if any. The shares are scheduled to begin trading on The NASDAQ Global Select Market on November 11, 2015 under the ticker symbol "VYGR." The offering is expected to close on November 16, 2015, subject to customary closing conditions.
Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Wedbush PacGrow and Nomura are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with, and was declared effective by, the Securities and Exchange Commission. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. This offering will be made only by means of a prospectus. A preliminary prospectus describing the terms of the offering was filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140, and from Piper Jaffray & Co. by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
CONTACT: Investor Relations: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 Sarah@sternir.com Media: Dan Budwick Pure Communications, Inc. 973-271-6085 email@example.comSource:Voyager Therapeutics, Inc.